Lithuanian Prostate Diagnostics Implementation Guide
0.0.1 - ci-build Lithuania flag

Lithuanian Prostate Diagnostics Implementation Guide, published by Lithuanian Medical Library. This guide is not an authorized publication; it is the continuous build for version 0.0.1 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7LT/ig-lt-prostate/ and changes regularly. See the Directory of published versions

Questionnaire: Prostate pathology structured report

Official URL: https://hl7.lt/fhir/prostate/Questionnaire/prostate-pathology-espbi Version: 0.1.0
Computable Name: ProstatePathologyEspbi

Language: en

Structure
LinkIDTextCardinalityTypeDescription & Constraintsdoco
.. ProstatePathologyEspbi Questionnaire https://hl7.lt/fhir/prostate/Questionnaire/prostate-pathology-espbi#0.1.0
... grp-specimen Specimen and macroscopic context 0..1 group Value Set:
.... bioptate-length-mm Bioptate length (mm) 0..1 quantity Value Set:
.... specimen-quality Quality of materials 0..1 coding Value Set:
Options: 3 options
... grp-treatment-effect Treatment effect (selected) 0..1 group Value Set:
.... treatment-effect Treatment effect on tumour 0..1 coding Value Set:
Options: 5 options
... grp-histology Histological tumour type 0..1 group Value Set:
.... histological-type Primary histological type 0..1 coding Value Set:
Options: 16 options
.... histological-comment Histological type comment 0..1 text Value Set:
.... isup-grade-group International Society of Urological Pathology grade group 0..1 coding Value Set:
Options: 5 options
... grp-idc-cribriform IDC and cribriform 0..1 group Value Set:
.... idc-status Intraductal carcinoma (IDC) 0..1 coding Value Set:
Options: 2 options
.... cribriform-status Cribriform glands 0..1 coding Value Set:
Options: 3 options
... grp-additional-grade-burden Additional grade and tumour burden (subset) 0..1 group Value Set:
.... pattern4-pct-band Quantity of Pattern 4 (percent band) 0..1 coding Value Set:
Options: 4 options
.... tumor-percent-in-biopsy Tumour percentage in biopsy tissue 0..1 coding Value Set:
Options: 4 options
... grp-invasion Local invasion (subset) 0..1 group Value Set:
.... periprostatic-fat-invasion Tumour infiltration in periprostatic adipose tissue 0..1 coding Value Set:
Options: 3 options
.... perineural-invasion Perineural invasion 0..1 coding Value Set:
Options: 4 options
.... perineural-invasion-notes Perineural invasion notes 0..1 text Value Set:
.... lymphovascular-invasion Lymphatic and/or vascular tumour invasion 0..1 coding Value Set:
Options: 4 options
.... lymphovascular-invasion-notes Lymphovascular invasion notes 0..1 text Value Set:

doco Documentation for this format

Options Sets

Answer options for specimen-quality

  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#specimen-satisfactory ("Specimen satisfactory for evaluation")
  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#specimen-limited ("Specimen satisfactory but limited")
  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#specimen-insufficient ("Insufficient tissue for diagnosis")

Answer options for treatment-effect

  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#treatment-unknown ("Treatment effect unknown")
  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#treatment-unidentifiable ("Treatment effect unidentifiable")
  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#treatment-radiotherapy ("Observed radiotherapy effect")
  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#treatment-hormone ("Observed hormone therapy effect")
  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#treatment-other ("Observed other therapy effect")

Answer options for histological-type

  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#hist-acinar ("Acinar adenocarcinoma (conventional)")
  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#hist-acinar-signet-ring ("Acinar adenocarcinoma, signet-ring cell-like")
  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#hist-acinar-pleomorphic ("Acinar adenocarcinoma, pleomorphic giant cell")
  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#hist-acinar-sarcomatoid ("Acinar adenocarcinoma, sarcomatoid")
  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#hist-acinar-pin-like ("Acinar adenocarcinoma, PIN-like")
  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#hist-idc-isolated ("Isolated intraductal carcinoma")
  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#hist-ductal ("Ductal adenocarcinoma")
  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#hist-adenosquamous ("Adenosquamous carcinoma")
  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#hist-squamous ("Squamous cell carcinoma")
  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#hist-basal-cell ("Basal cell (adenoid cystic) carcinoma")
  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#hist-neuro-adeno ("Adenocarcinoma with neuroendocrine differentiation")
  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#hist-neuro-well-diff ("Well-differentiated neuroendocrine tumor")
  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#hist-neuro-small-cell ("Small cell neuroendocrine carcinoma")
  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#hist-neuro-large-cell ("Large cell neuroendocrine carcinoma")
  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#hist-unassessable ("Carcinoma, type unassessable")
  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#hist-other ("Other histological type (see comment)")

Answer options for isup-grade-group

  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#isup-gg1 ("ISUP Grade Group 1 (Gleason 3+3)")
  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#isup-gg2 ("ISUP Grade Group 2 (Gleason 3+4)")
  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#isup-gg3 ("ISUP Grade Group 3 (Gleason 4+3)")
  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#isup-gg4 ("ISUP Grade Group 4 (Gleason 4+4 or equivalent)")
  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#isup-gg5 ("ISUP Grade Group 5 (Gleason 4+5 / 5+4 / 5+5)")

Answer options for idc-status

  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#idc-absent ("Intraductal carcinoma not identified")
  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#idc-present ("Intraductal carcinoma identifiable")

Answer options for cribriform-status

  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#cribriform-na ("Cribriform not applicable")
  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#cribriform-unknown ("Cribriform undefined")
  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#cribriform-present ("Cribriform identifiable")

Answer options for pattern4-pct-band

  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#pattern4-pct-na ("Pattern 4 %: not applicable")
  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#pattern4-pct-lte5 ("Pattern 4 %: ≤5%")
  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#pattern4-pct-6-10 ("Pattern 4 %: 6–10%")
  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#pattern4-pct-gt40 ("Pattern 4 %: >40%")

Answer options for tumor-percent-in-biopsy

  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#tumor-pct-lt1 ("Tumour % in biopsy: <1%")
  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#tumor-pct-1-5 ("Tumour % in biopsy: 1–5%")
  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#tumor-pct-gt90 ("Tumour % in biopsy: >90%")
  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#tumor-pct-uneval ("Tumour %: cannot be evaluated")

Answer options for periprostatic-fat-invasion

  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#periprostatic-unknown ("Periprostatic fat invasion: unidentifiable")
  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#periprostatic-absent ("Periprostatic fat invasion: not identified")
  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#periprostatic-present ("Periprostatic fat invasion: present")

Answer options for perineural-invasion

  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#perineural-absent ("Perineural invasion not identified")
  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#perineural-present ("Perineural invasion present")
  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#perineural-ambiguous ("Perineural invasion ambiguous")
  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#perineural-uneval ("Perineural invasion cannot be evaluated")

Answer options for lymphovascular-invasion

  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#lymphovascular-absent ("Lymphovascular invasion unidentifiable / not available")
  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#lymphovascular-present ("Lymphovascular invasion identifiable")
  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#lymphovascular-ambiguous ("Lymphovascular invasion ambiguous")
  • https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#lymphovascular-uneval ("Lymphovascular invasion cannot be evaluated")

Language: en

Specimen and macroscopic context

  • linkId: grp-specimen
  • Answers:

Bioptate length (mm)

  • linkId: bioptate-length-mm
  • Answers:

Quality of materials

Treatment effect (selected)

  • linkId: grp-treatment-effect
  • Answers:

Treatment effect on tumour

Histological tumour type

  • linkId: grp-histology
  • Answers:

Primary histological type

Histological type comment

  • linkId: histological-comment
  • Answers:

Grade (ISUP)

  • linkId: grp-grade
  • Answers:

International Society of Urological Pathology grade group

IDC and cribriform

  • linkId: grp-idc-cribriform
  • Answers:

Intraductal carcinoma (IDC)

Cribriform glands

Additional grade and tumour burden (subset)

  • linkId: grp-additional-grade-burden
  • Answers:

Quantity of Pattern 4 (percent band)

Tumour percentage in biopsy tissue

Local invasion (subset)

  • linkId: grp-invasion
  • Answers:

Tumour infiltration in periprostatic adipose tissue

Perineural invasion

Perineural invasion notes

  • linkId: perineural-invasion-notes
  • Answers:

Lymphatic and/or vascular tumour invasion

Lymphovascular invasion notes

  • linkId: lymphovascular-invasion-notes
  • Answers:

Language: en

LinkIDDescription & Constraintsdoco
.. grp-specimen Value Set:
... bioptate-length-mm Value Set:
... specimen-quality Value Set:
Options: 3 options
.. grp-treatment-effect Value Set:
... treatment-effect Value Set:
Options: 5 options
.. grp-histology Value Set:
... histological-type Value Set:
Options: 16 options
... histological-comment Value Set:
.. grp-grade Value Set:
... isup-grade-group Value Set:
Options: 5 options
.. grp-idc-cribriform Value Set:
... idc-status Value Set:
Options: 2 options
... cribriform-status Value Set:
Options: 3 options
.. grp-additional-grade-burden Value Set:
... pattern4-pct-band Value Set:
Options: 4 options
... tumor-percent-in-biopsy Value Set:
Options: 4 options
.. grp-invasion Value Set:
... periprostatic-fat-invasion Value Set:
Options: 3 options
... perineural-invasion Value Set:
Options: 4 options
... perineural-invasion-notes Value Set:
... lymphovascular-invasion Value Set:
Options: 4 options
... lymphovascular-invasion-notes Value Set:

doco Documentation for this format

Test this Questionnaire

Try this questionnaire out:

Responses for this Questionnaire